Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006375 · ClinicalTrials.gov registry record · Phase 1
LY293111 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00006375: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00006375 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006375, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of LY293111 in treating patients who have advanced solid tumors.
Interventions
- DRUG LY293111
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2003-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006375
The ClinicalTrials.gov registry entry for NCT00006375 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY293111 is the first listed.
NCT00006375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006375 about?
NCT00006375 is a clinical study titled "LY293111 in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of LY293111 in treating patients who have advanced solid tumors.
What is the current status of trial NCT00006375?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-06. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00006375?
The interventions under investigation include: LY293111 (DRUG).
Who is sponsoring clinical trial NCT00006375?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.